In this Demystifying Medicine video from McMaster University, learn more about idiopathic pulmonary fibrosis (IPF), a scleroderma-related condition that currently has no known cause.
Back in February, researchers presented a study investigating the therapeutic effect of the monoclonal antibody CM-101 in animal models of systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF).
According to the Scleroderma Foundation, pulmonary disease is an important component of systemic sclerosis (SSc). Approximately 80% of patients with SSc have some evidence of pulmonary disease.
Scleroderma News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.